NatWest Group plc Buys Shares of 73,702 Gilead Sciences, Inc. (NASDAQ:GILD)

NatWest Group plc acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 73,702 shares of the biopharmaceutical company's stock, valued at approximately $6,808,000. Gilead Sciences accounts for about 2.0% of NatWest Group plc's portfolio, making the stock its 21st biggest position.

Other large investors have also modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $25,000. HHM Wealth Advisors LLC raised its position in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 154 shares in the last quarter. Valued Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 161 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Gilead Sciences during the 4th quarter worth $28,000. Finally, Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, Director Jeffrey Bluestone sold 6,788 shares of the company's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares of the company's stock, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the firm's stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 572,824 shares of company stock worth $53,611,715 over the last three months. 0.16% of the stock is owned by insiders.

Gilead Sciences Trading Down 2.0 %

Gilead Sciences stock traded down $2.00 during trading on Friday, reaching $96.04. The company had a trading volume of 7,182,199 shares, compared to its average volume of 6,866,207. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $100.51. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock's 50 day moving average price is $93.04 and its two-hundred day moving average price is $86.76. The firm has a market capitalization of $119.69 billion, a price-to-earnings ratio of 1,067.11, a PEG ratio of 1.25 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the prior year, the firm posted $2.29 EPS. The business's revenue for the quarter was up 7.0% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on GILD. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Morgan Stanley raised Gilead Sciences from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $87.00 to $113.00 in a report on Friday, January 10th. UBS Group lifted their price target on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Finally, Wolfe Research started coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They issued an "outperform" rating and a $110.00 price objective on the stock. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.